Mario Sznol

Mario Sznol

Oncology

35 Park St
# Np8
New Haven, CT 06519

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 154 publications

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Journal: Journal for immunotherapy of cancer

Published: February 02, 2026

Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies.

Bridging the gap: A systematic approach to integrating serum and plasma proteomic datasets for biomarker studies.

Journal: Journal of pharmaceutical and biomedical analysis

Published: August 24, 2025

Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Ex Vivo Expansion of Melanoma Tumor-Infiltrating Lymphocytes Leads to a Dominant Exhausted T-cell Population with a Lack of Memory Markers.

Journal: Cancer immunology research

Published: July 21, 2025

Clonal determinants of organotropism and survival in metastatic uveal melanoma.

Clonal determinants of organotropism and survival in metastatic uveal melanoma.

Journal: NPJ precision oncology

Published: July 15, 2025

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy.

Journal: Journal for immunotherapy of cancer

Published: May 06, 2025

Survival of patients with metastatic renal cell carcinoma with or without brain metastases.

Survival of patients with metastatic renal cell carcinoma with or without brain metastases.

Journal: The oncologist

Published: April 27, 2025

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 06, 2025

Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1.

Improving immunotherapy responses by dual inhibition of macrophage migration inhibitory factor and PD-1.

Journal: JCI insight

Published: January 23, 2025

LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.

LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis.

Journal: Oncogene

Published: December 29, 2024

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

Journal: Cancer research communications

Published: December 17, 2024

Non-invasive profiling of the tumour microenvironment with spatial ecotypes.

Non-invasive profiling of the tumour microenvironment with spatial ecotypes.

Journal: Nature

Published: December 04, 2024

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 06, 2024

Showing 1-12 of 154

Last Updated: 09/26/2026